1. Generics Bulletin

Vyvanse Generics Roll Out In US As Suppliers Work To Meet Demand

Launches Of Lisdexamfetamine Capsules Confirmed By Hikma And Mallinckrodt

 
• By Dave Wallace

Hot on the heels of multiple US FDA approvals for rivals to the blockbuster ADHD brand Vyvanse, generics suppliers have confirmed launches – and with drugs in this category currently facing shortages, developers are eyeing significant demand.

Pile of orange and white capsules
Generic versions of Vyvanse are reaching the US market • Source: Shutterstock

Late August’s loss of exclusivity for Vyvanse (lisdexamfetamine) in the US represents one of the most significant off-patent opportunities of 2023, and at least two suppliers are already in the market with their versions of the blockbuster attention-deficit/hyperactivity disorder treatment, amid suggestions that demand will be particularly high given current shortages of ADHD drugs.

Coming immediately after the US Food and Drug Administration approved more than a dozen generic versions of lisdexamfetamine in 10mg, 20mg, 30mg 40mg, 50mg, 60mg and 70mg strengths – as well as a handful of generic lisdexamfetamine chewable tablets in 10mg, 20mg, 30mg 40mg, 50mg and 60mg strengths (see sidebar) –

More from Generics

More from Products

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.